Apogee Financial Statements From 2010 to 2025

APGE Stock   38.83  1.52  3.77%   
Apogee Therapeutics, financial statements provide useful quarterly and yearly information to potential Apogee Therapeutics, Common investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Apogee Therapeutics, financial statements helps investors assess Apogee Therapeutics,'s valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Apogee Therapeutics,'s valuation are summarized below:
Market Capitalization
2.3 B
Earnings Share
(3.30)
Apogee Therapeutics, Common does not presently have any fundamental signals for analysis.
Check Apogee Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Apogee Therapeutics,'s main balance sheet or income statement drivers, such as Net Interest Income of 36.5 M, Interest Income of 36.5 M or Depreciation And Amortization of 7.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.66. Apogee financial statements analysis is a perfect complement when working with Apogee Therapeutics, Valuation or Volatility modules.
  
Check out the analysis of Apogee Therapeutics, Correlation against competitors.

Apogee Therapeutics, Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets479.4 M754 M225.7 M
Slightly volatile
Other Current Liabilities18.7 M24.3 M11.5 M
Slightly volatile
Total Current Liabilities21.7 M28.6 M12.5 M
Slightly volatile
Accounts Payable1.3 M1.1 M623.7 K
Slightly volatile
Cash109.9 M141.8 M146.5 M
Slightly volatile
Cash And Short Term Investments391.6 M520.7 M205.1 M
Slightly volatile
Common Stock Shares Outstanding57.4 M55.2 M51.4 M
Slightly volatile
Liabilities And Stockholders Equity427.3 M754 M107 M
Slightly volatile
Other Current Assets9.5 M9.1 M1.5 M
Slightly volatile
Other Stockholder Equity653.5 MB345 M
Slightly volatile
Total Liabilities25.2 M37.2 M13.3 M
Slightly volatile
Net Invested Capital611.4 MB249 M
Slightly volatile
Total Current Assets396.1 M529.7 M206.3 M
Slightly volatile
Net Working Capital374.4 M501.2 M193.8 M
Slightly volatile
Common Stock8559003.6 M
Slightly volatile
Short and Long Term Debt Total7.6 M11.8 MM
Slightly volatile
Non Currrent Assets Other116.2 M210.9 M20.8 M
Slightly volatile
Short Term Debt2.4 M3.2 M1.3 M
Slightly volatile
Long Term Investments168.3 M189.4 M206.5 M
Slightly volatile

Apogee Therapeutics, Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Income36.5 M34.7 M5.1 M
Slightly volatile
Depreciation And Amortization7.7 M8.1 M28.8 M
Slightly volatile
Selling General Administrative28.1 M49 M8.7 M
Slightly volatile
Other Operating Expenses68.1 M107 M41.7 M
Slightly volatile
Research Development96.8 M167.9 M43.4 M
Slightly volatile
Total Operating Expenses124.9 M216.9 M52.1 M
Slightly volatile
Tax Provision14.4 K16.2 K17.7 K
Slightly volatile
Reconciled Depreciation151.2 K170.1 K185.5 K
Slightly volatile

Apogee Therapeutics, Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation24.5 M23.3 M5.1 M
Slightly volatile
Begin Period Cash Flow117 M118.6 M160.8 M
Slightly volatile
Issuance Of Capital Stock358.3 M493.5 M209.7 M
Slightly volatile
Total Cash From Financing Activities297.3 M495.1 M69.4 M
Slightly volatile
End Period Cash Flow110 M142.1 M146.6 M
Slightly volatile
Depreciation151.2 K170.1 K185.5 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Book Value Per Share13.6412.98684.4109
Slightly volatile
Capex To Depreciation4.885.495.9815
Slightly volatile
Cash Per Share5.49.43313.8504
Slightly volatile
Income Quality0.60.93980.4873
Slightly volatile
Net Debt To EBITDA1.090.59921.3171
Slightly volatile
Current Ratio14.1818.547415.6359
Slightly volatile
Tangible Book Value Per Share13.6412.98684.4109
Slightly volatile
Debt To Equity0.00870.01650.0063
Slightly volatile
Capex Per Share0.02190.02090.0056
Slightly volatile
Graham Net Net5.058.75993.5999
Slightly volatile
Interest Debt Per Share0.120.21440.1701
Slightly volatile
Debt To Assets0.00830.01570.0059
Slightly volatile
Ebt Per Ebit1.0E-41.0E-41.1085
Slightly volatile
Effective Tax Rate7.0E-48.0E-48.0E-4
Slightly volatile
Long Term Debt To Capitalization0.00950.01070.0116
Slightly volatile
Total Debt To Capitalization0.00860.01620.0062
Slightly volatile
Debt Equity Ratio0.00870.01650.0063
Slightly volatile
Quick Ratio14.1818.547415.6359
Slightly volatile
Cash Ratio9.524.964613.6308
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.81.00670.9899
Slightly volatile
Debt Ratio0.00830.01570.0059
Slightly volatile

Apogee Therapeutics, Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.3 B2.5 B1.2 B
Slightly volatile
Enterprise Value1.2 B2.4 B1.1 B
Slightly volatile

Apogee Fundamental Market Drivers

Cash And Short Term Investments520.7 M

Apogee Upcoming Events

12th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
12th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Apogee Therapeutics, Financial Statements

Apogee Therapeutics, stakeholders use historical fundamental indicators, such as Apogee Therapeutics,'s revenue or net income, to determine how well the company is positioned to perform in the future. Although Apogee Therapeutics, investors may analyze each financial statement separately, they are all interrelated. For example, changes in Apogee Therapeutics,'s assets and liabilities are reflected in the revenues and expenses on Apogee Therapeutics,'s income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Apogee Therapeutics, Common. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Apogee Therapeutics, is a strong investment it is important to analyze Apogee Therapeutics,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Apogee Therapeutics,'s future performance. For an informed investment choice regarding Apogee Stock, refer to the following important reports:
Check out the analysis of Apogee Therapeutics, Correlation against competitors.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apogee Therapeutics,. If investors know Apogee will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apogee Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.30)
Return On Assets
(0.23)
Return On Equity
(0.33)
The market value of Apogee Therapeutics, is measured differently than its book value, which is the value of Apogee that is recorded on the company's balance sheet. Investors also form their own opinion of Apogee Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Apogee Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apogee Therapeutics,'s market value can be influenced by many factors that don't directly affect Apogee Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apogee Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Apogee Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apogee Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.